Adaptation of Aspergillus Niger to Multiple Agents Whose Action Mechanisms Are Different

Total Page:16

File Type:pdf, Size:1020Kb

Adaptation of Aspergillus Niger to Multiple Agents Whose Action Mechanisms Are Different Jpn. J. Med. Mycol. Vol. 36, 19-24, 1995 ISSN 0916-4804 Original Article Adaptation of Aspergillus niger to Multiple Agents Whose Action Mechanisms are Different Hideaki Matsuoka1, Jong-Chul Park1, Yasuyuki Nemoto1, Satoru Yamada2, Weimin Jing3, Yuansong Chen3, Kosuke Takatori4, Hiroshi Kurata5 1Department of Biotechnology, Faculty of Technology, Tokyo University of Agriculture and Technology, 2-24-16, Nakamachi, Koganei, Tokyo 184, Japan 2Research and Development Division, Bio-Liken Inc., 1-5-8, Iwamotocho, Chiyoda-ku, Tokyo 101, Japan 3Research and Development Division, Hidan Co. Ltd., 627, Hananoi, Kashiwa, Chiba 277, Japan 4Hatano Research Institute, Food & Drug Safety Center, 729-5, Ochiai, Hadano, Kanagawa 257, Japan 5The Tokyo Kembikyoin Foundation, 4-8-32, Kudanminami, Chiyoda-ku, Tokyo 102, Japan (Received: 9, August 1994. Accepted: 9, September 1994] Abstract Adaptation of Aspergillus niger to amphotericin B (AMPH) and two imidazoles (miconazole (MCZ) and ketoconazole (KCZ)) was observed at a single hypha level with a continuous measurement system. It was found that a test hypha adapted to MCZ or KCZ was also adapted to AMPH but that a hypha adapted to AMPH was not adapted either to MCZ or KCZ. These adaptation phenomena to respective agents did not occur after incubation in the medium supplemented with ergosterol. The cross adaptation phenomena were suspected to be due to modification of the synthesis pathway of ergosterol and related derivatives. Key words: adaptation, hyphal growth rate, Aspergillus niger, amphotericin B, miconazole, ketoconazole. rienced by many mycologists and microbiologists Introduction 5-9). The newly developed BCT system has dem- A single hypha-based microbioassay has recently onstrated those adaptation phenomena much more been proposed and applied to the evaluation of clearly by tracing the same hypha throughout. antifungal activity of antimycotics against filamen- In the present study, we examined the responses tous fungi1-37). This microbioassay is based on the of a test hypha to the repeated actions of different continuous measurement of the growth of a test agents for the purpose of clarifying whether the hypha under a microscope. The movement of the hypha is addpted to respective agents exclusively. hyphal apex can be precisely traced automatically Materials and Methods by a computer-aided system, which is called Bio- Cell Tracer (BCT). BCT enables the continuous Microorganism measurement of the responses to repeated actions Aspergillus niger IFO 6661 was maintained at 4 of agents to the same hypha. Such a continuous C on slants of potato dextrose agar (PDA, Difco measurement of the same hypha is impossible by Laboratories, Detroit, Mich., USA). The mould conventional assay methods dealing with massive was precultured on PDA slants at 28CCfor 7 days hyphae. prior to use. The authors previously examined the responses Antifungal agents and ergosterol of a test hypha of Aspergillus niger to the repeated Amphotericin B (AMPH) and miconazole (MCZ) actions of salt and observed adaptation phenomena were purchased from Sigma (St. Louis, Mo., USA), 4), which were similar to those formerly expe- and ketoconazole (KCZ) was purchased from 20 真 菌 誌 第36巻 第1号 平 成7年 Biomol Research Laboratories, Inc. (Plymouth to confirm that a test hypha met this criterion, Meeting, Pa., USA). Stock solutions of these the following criteria were introduced: agents were prepared at 10 mg/ml in dimethyl 1. The growth of a test hypha is inhibited sulphoxide (DMSO) and stored at -20C. These remarkably by the first action of an agent, stock solutions were used within 7 days. Test and the growth rate initially drops to zero. solutions of AMPH, MCZ and KCZ were prepared 2. The growth recovers during the first action by diluting the stock solutions with potato dextrose or after removal of the agent. broth (PDB, Difco Laboratories) before use. 3. The second action of the same agent at the Final concentrations of DMSO in the test solu- same concentration as the first action causes tions were less than 0.25% (v/v). Ergosterol no remarkable inhibition effect on the growth purchased from Sigma was dissolved in DMSO of the same hypha. and 2-propanol (2:1, v/v) to prepare 10 mg/ml When these criteria were satisfied, another stock solution immediately prior to use. This stock agent was applied in order to check whether the solution was diluted with PDB and applied to adaptation was exclusive. the assays. Results System for measuring hyphal growth Hyphal growth was measured with a BCT system Pre-exposure growth rate (Hidan Co., Ltd., Chiba, Japan). The system A test hypha was arbitrarily selected on the TV consists of a microscope, a charge coupled device monitor and its growth rate was measured for (CCD) camera, an image analysing system, and 30 min. If the rate was not stable and variation a microscope stage controller1,4). A reaction vessel exceeded 20%, another hypha was selected as a was set on the microscope stage. The inner bottom test hypha and the growth rate was again meas- surface of the reaction vessel was coated with a ured. Once stable, the average of the growth rate solution of 0.01% (w/v) filter-sterilized poly-L- during a 30 min measurement was defined as lysine (poly-L-lysine hydrobromide, MW 70,000- the pre-exposure growth rate. The average and 150,000, Sigma). In the image obtained through standard deviation of the pre-exposure growth rate a microscope, an appropriate hypha was selected were determined as 3.96 0.82 pm/min from the and its growth was traced automatically. Its data obtained with 81 test hyphae. growth rate was calculated from the distance the Optimum concentrations of agents for the hypha lengthened during the measuring interval adaptation experiment (30 sec). AMPH was applied to hyphae at various Assay procedure concentrations in the range of 0.01-1.0 ig/ml. The spores from a 7-day-old culture grown on When the concentration was 0.075 pg/ml, the a PDA slant at 2 8C were harvested in sterile growth rate once became zero and then returned saline containing 0.05% (v/v) Tween 80. After to the initial level within 30 min as shown in washing three times with sterile distilled water, one Fig. 1-A. After washing with fresh medium, the microlitre of the spore suspension at a concentra- same concentration of AMPH was applied again tion of 2X108 spores/ml was placed onto the poly- to the hypha. No response was obtained within L-lysine-coated glass plate of the reaction vessel 30 min. When the concentration was higher, the and left standing for 30 min. Then the suspension first action of AMPH caused the zero growth was removed, and one millilitre PDB was poured rate more rapidly than did 0.075 pg/mi. The into the reaction vessel. The reaction vessel was second action, however, still caused the same incubated for 24h at 28C to form a colony growth inhibition. On the other hand, at lower about 5 mm in diameter. The reaction vessel was concentrations, the growth rate did not become then mounted on the microscope stage, and the zero within 30 min during the first action. medium was replaced by one millilitre fresh PDB Therefore, the optimum concentration of AMPH and left to stand for 30 min at 28C. An appro- was determined to be 0.075 ig/ml. priate hypha was selected on the TV monitor In the same manner, the effects of MCZ and and its growth rate was measured for 30 min. KCZ were examined in the range 0.001-1.0 ug After confirming that the growth rate was stable, /ml and 0.01-5.0 ag/ml, respectively. The the medium was replaced by a PDB containing optimum concentrations of MCZ and KCZ were an antifungal agent. determined as 0.01 g/ml and 0.5 ig/ml, Confirmation of adaptation to an anti- respectively. These response curves are shown in fungal agent Fig. 1-B, C. A test hypha needs to be adapted to an agent before being exposed to another agent. In order Jpn. J. Med. Mycol. Vol. 36 (No. 1), 1995 21 A A B B C Fig. 2. Effects of (A) MCZ or (B) KCZ on the hyphal growth of A, niger previously adapted to AMPH. Refer to the legend for Fig. 1. in response to MCZ was identical with that of Fig. 1-B; therefore, the acquisition of adaptation to AMPH had no effect on the sensitivity to MCZ. Acquisition of adaptation to AMPH also had no effect on the sensitivity to KCZ, as shown in Fig. 2-B. In contrast, a hypha adapted either to 0.01 ig/ml MCZ or to 0.5 eg/ml KCZ beforehand was insensitive to the other two agents, as shown in Figs. 3 and 4. Fig, 1. Adaptation of A. niger hyphal growth to anti- fungal agents. (A) AMPH; (B) MCZ; (C) KCZ Effect of ergosterol on the elimination of At the arrows marked AMPH, MCZ, and KCZ, adaptation PDB was replaced by PDB containing 0.075 ug/ml After confirming the adaptation to 0.07ug/ AMPH, 0.01 ug/ml MCZ, and 0.5 ug/ml KCZ, ml AMPH, the PDB containing 10.0 ag/ml respectively. At the arrows marked "Washing", PDB ergosterol was applied to the test hypha. Then, containing an antifungal agent was replaced by anti- after 60 min incubation, 0.075 g/ml AMPH fungal-free PDB. Experiments were done in triplicate. was applied to the hypha. As shown in Fig. 5-A, The data are representative results obtained with respective experiments. the growth rate decreased sharply, indicating the adaptation had been eliminated. The treatment Responses of an adaptation-acquired hypha with PDB containing ergosterol was also effective to different agents in eliminating the adaptation to MCZ and KCZ After confirming that a test hypha was adapted as demonstrated in Fig.
Recommended publications
  • Systemic Antifungal Drug Use in Belgium—
    Received: 7 October 2018 | Revised: 28 March 2019 | Accepted: 14 March 2019 DOI: 10.1111/myc.12912 ORIGINAL ARTICLE Systemic antifungal drug use in Belgium—One of the biggest antifungal consumers in Europe Berdieke Goemaere1 | Katrien Lagrou2,3* | Isabel Spriet4,5 | Marijke Hendrickx1 | Eline Vandael6 | Pierre Becker1 | Boudewijn Catry6,7 1BCCM/IHEM Fungal Collection, Service of Mycology and Aerobiology, Sciensano, Summary Brussels, Belgium Background: Reports on the consumption of systemic antifungal drugs on a national 2 Department of Microbiology and level are scarce although of high interest to compare trends and the associated epi- Immunology, KU Leuven, Leuven, Belgium 3Clinical Department of Laboratory demiology in other countries and to assess the need for antifungal stewardship Medicine, National Reference Centre for programmes. Mycosis, University Hospitals Leuven, Leuven, Belgium Objectives: To estimate patterns of Belgian inpatient and outpatient antifungal use 4Department of Pharmaceutical and and provide reference data for other countries. Pharmacological Sciences, KU Leuven, Methods: Consumption records of antifungals were collected in Belgian hospitals Leuven, Belgium between 2003 and 2016. Primary healthcare data were available for the azoles for 5Pharmacy Department, University Hospitals Leuven, Leuven, Belgium the period 2010-2016. 6 Healthcare‐Associated Infections and Results: The majority of the antifungal consumption resulted from prescriptions of Antimicrobial Resistance, Sciensano, Brussels, Belgium fluconazole and itraconazole in the ambulatory care while hospitals were responsible 7Faculty of Medicine, Université Libre de for only 6.4% of the total national consumption and echinocandin use was limited. Bruxelles (ULB), Brussels, Belgium The annual average antifungal consumption in hospitals decreased significantly by Correspondence nearly 25% between 2003 and 2016, due to a decrease solely in non-university hos- Berdieke Goemaere, Sciensano, Mycology pitals.
    [Show full text]
  • IJP: Drugs and Drug Resistance 8 (2018) 246–264
    IJP: Drugs and Drug Resistance 8 (2018) 246–264 Contents lists available at ScienceDirect IJP: Drugs and Drug Resistance journal homepage: www.elsevier.com/locate/ijpddr Genomic and transcriptomic alterations in Leishmania donovani lines T experimentally resistant to antileishmanial drugs Alberto Rastrojoa,1, Raquel García-Hernándezb,1, Paola Vargasb, Esther Camachoa, Laura Corvoa, Hideo Imamurac, Jean-Claude Dujardinc, Santiago Castanysb, Begoña Aguadoa, ∗∗ ∗ Francisco Gamarrob, , Jose M. Requenaa, a Centro de Biología Molecular “Severo Ochoa” (CSIC-UAM), Universidad Autónoma de Madrid, Madrid, Spain b Instituto de Parasitología y Biomedicina ‘‘López-Neyra’’ (IPBLN-CSIC), Granada, Spain c Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium ARTICLE INFO ABSTRACT Keywords: Leishmaniasis is a serious medical issue in many countries around the World, but it remains largely neglected in Leishmania donovani terms of research investment for developing new control and treatment measures. No vaccines exist for human Genome use, and the chemotherapeutic agents currently used are scanty. Furthermore, for some drugs, resistance and Transcriptome treatment failure are increasing to alarming levels. The aim of this work was to identify genomic and tran- Trivalent antimony criptomic alterations associated with experimental resistance against the common drugs used against VL: tri- Amphotericin B valent antimony (SbIII, S line), amphotericin B (AmB, A line), miltefosine (MIL, M line) and paromomycin (PMM, Miltefosine ff fi Paromomycin P line). A total of 1006 di erentially expressed transcripts were identi ed in the S line, 379 in the A line, 146 in 24-Sterol methyltransferase the M line, and 129 in the P line. Also, changes in ploidy of chromosomes and amplification/deletion of par- D-lactate dehydrogenase ticular regions were observed in the resistant lines regarding the parental one.
    [Show full text]
  • Nystatin and Triamcinolone Acetonide Cream, USP Nystatin And
    FRONT BACK Nystatin and Triamcinolone Acetonide Cream, USP PK-1111-3 corticosteroids. 45 Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to Nystatin and Triamcinolone Acetonide Ointment, USP systemic toxicity (see PRECAUTIONS, Pediatric Use). Rx only If irritation or hypersensitivity develops with the combination nystatin and triamcinolone acetonide, treatment should be discontinued and appropriate therapy instituted. FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE Information for the Patient: Patients using this medication should receive the following information and DESCRIPTION: Nystatin and Triamcinolone Acetonide Cream and Ointment for dermatologic use contain the instructions: antifungal agent nystatin and the synthetic corticosteroid triamcinolone acetonide. 1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. Nystatin is a polyene antimycotic obtained from Streptomyces noursei. It is a yellow to light tan powder with a 2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed. cereallike odor, very slightly soluble in water, and slightly to sparingly soluble in alcohol. Structural formula: 3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occluded (see CH3 DOSAGE AND ADMINISTRATION). O H CH3 4. Patients should report any signs of local adverse reactions. O H HO OH H2N 5. When using this medication in the inguinal area, patients should be advised to apply the cream or ointment OH OH sparingly and to wear loose fitting clothing. CH3 H H H3C 6. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being OH O COOH treated in the diaper area, as these garments may constitute occlusive dressings.
    [Show full text]
  • WO 2017/009265 Al 19 January 2017 (19.01.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/009265 Al 19 January 2017 (19.01.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A01N 31/06 (2006.01) A01N 37/04 (2006.01) kind of national protection available): AE, AG, AL, AM, A0 37/00 (2006.01) A01P 1/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A0 37/02 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/EP2016/066368 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 8 July 2016 (08.07.2016) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 15 12 135.3 10 July 2015 (10.07.2015) GB GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: IPABC LTD [GB/GB]; The Die-Pat Centre, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Broad March, Broad March, Daventry, Northamptonshire DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, NN1 1 4HE (GB).
    [Show full text]
  • Amphotericin B Amphocil
    Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended Amphotericin B Amphocil Abelcet DE/W/009/pdWS/001 Rapporteur: Germany Finalisation procedure (day 120): 24.11.2017 Amphotericin B DE/W/009/pdWS/001 Seite 1 TABLE OF CONTENTS I. Executive Summary ....................................................................................................... 4 II. RecommendatioN .......................................................................................................... 4 III. INTRODUCTION ............................................................................................................. 6 IV. SCIENTIFIC DISCUSSION .............................................................................................. 7 IV.1 Information on the pharmaceutical formulation used in the clinical studies .............. 7 IV.2 Non-clinical aspects ................................................................................................................... 9 IV.3 Clinical aspects .......................................................................................................................... 10 V. MEMBER STATES Overall Conclusion AND RECOMMENDATION ........................... 31 VI. List of Medicinal products and marketing authorisation holders involved ............. 33 Amphotericin B DE/W/009/pdWS/001 Page 2/33 ADMINISTRATIVE INFORMATION Invented name of the medicinal See section VI product(s): INN (or common name) of the active Amphotericin B substance(s):
    [Show full text]
  • Nystatin Cream USP, 100,000 Units Per Gram Rx Only
    NYSTATIN- nystatin cream Rebel Distributors Corp ---------- Nystatin Cream USP, 100,000 units per gram Rx only DESCRIPTION Nystatin Cream is for dermatologic use. Nystatin is a polyene antimycotic obtained from Streptomyces noursei. It is a yellow to light tan powder with a cereal-like odor, very soluble in water, and slightly to sparingly soluble in alcohol. Structural formula: Nystatin Cream contains the antifungal antibiotic nystatin at a concentration of 100,000 USP Nystatin Units per gram in an aqueous, perfumed cream base containing purified water, propylene glycol, methylparaben, propylparaben, white petrolatum, glyceryl monostearate, polyethylene glycol 400 monostearate, ceteareth-15, medical antifoam AF emulsion, aluminum hydroxide gel, titanium dioxide, sorbitol solution, and, if necessary, sodium hydroxide for pH adjustment. CLINICAL PHARMACOLOGY Nystatin is an antifungal antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. It probably acts by binding to sterols in the cell membrane of the fungus with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin is the first well tolerated antifungal antibiotic of dependable efficacy for the treatment of cutaneous, oral and intestinal infections caused by Candida (Monilia) albicans and other Candida species. It exhibits no appreciable activity against bacteria. Nystatin provides specific therapy for all localized forms of candidiasis. Symptomatic relief is rapid, often occurring within 24 to 72 hours after the initiation of treatment. Cure is effected both clinically and mycologically in most cases of localized candidiasis. INDICATIONS AND USAGE Nystatin Cream is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida (Monilia) albicans and other Candida species.
    [Show full text]
  • Impact of Antibiotics on the Proliferation and Differentiation of Human Adipose-Derived Mesenchymal Stem Cells
    Article Impact of Antibiotics on the Proliferation and Differentiation of Human Adipose-Derived Mesenchymal Stem Cells Aleksandra Skubis 1,*, Joanna Gola 1, Bartosz Sikora 1, Jolanta Hybiak 2, Monika Paul-Samojedny 3, Urszula Mazurek 1 and Marek J. Łos 4,5,6,*. 1 Department of Molecular Biology, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, 40-055 Katowice, Poland; [email protected] (J.G.); [email protected] (B.S.); [email protected] (U.M.) 2 Department of Pathology, Pomeranian Medical University, 70-204 Szczecin, Poland; [email protected] 3 Department of Medical Genetics, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, 40-055 Katowice, Poland; [email protected] 4 Małopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7A str., 30-387 Krakow, Poland 5 LinkoCare Life Sciences AB, 583 30 Linköping, Sweden 6 Centre de Biophysique Moléculaire, UPR4301 CNRS CS80054, Rue Charles Sadron, 45071 Orleans CEDEX 2, France * Correspondence: [email protected] (A.S.); [email protected] or [email protected] (M.J.Ł.); Tel.: +48-32-364-1020 (A.S.); +46-766-531-168 (M.J.Ł.); Received: 10 November 2017; Accepted: 20 November 2017; Published: 24 November 2017 Abstract: Adipose tissue is a promising source of mesenchymal stem cells. Their potential to differentiate and regenerate other types of tissues may be affected by several factors. This may be due to in vitro cell-culture conditions, especially the supplementation with antibiotics. The aim of our study was to evaluate the effects of a penicillin-streptomycin mixture (PS), amphotericin B (AmB), a complex of AmB with copper (II) ions (AmB-Cu2+) and various combinations of these antibiotics on the proliferation and differentiation of adipose-derived stem cells in vitro.
    [Show full text]
  • Methods and Kits for Detecting Fungal Infection Verfahren Und Kits Zum Nachweis Einer Pilzinfektion Procédés Et Trousses Pour Détecter Une Infection Fongique
    (19) TZZ_Z_T (11) EP 1 955 069 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/127 (2006.01) G01N 21/00 (2006.01) 18.03.2015 Bulletin 2015/12 G01N 33/53 (2006.01) G01N 33/569 (2006.01) (21) Application number: 06821559.9 (86) International application number: PCT/IL2006/001318 (22) Date of filing: 15.11.2006 (87) International publication number: WO 2007/057891 (24.05.2007 Gazette 2007/21) (54) METHODS AND KITS FOR DETECTING FUNGAL INFECTION VERFAHREN UND KITS ZUM NACHWEIS EINER PILZINFEKTION PROCÉDÉS ET TROUSSES POUR DÉTECTER UNE INFECTION FONGIQUE (84) Designated Contracting States: • TEJADA-SIMON M V ET AL: "Production of AT BE BG CH CY CZ DE DK EE ES FI FR GB GR polyclonal antibody against ergosterol HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI hemisuccinate using Freund’s and Titermax SK TR adjuvants" JOURNAL OF FOOD PROTECTION, DES MOINES, IO, US, vol. 61, no. 8, 1 August 1998 (30) Priority: 15.11.2005 US 736814 P (1998-08-01) , pages 1060-1063, XP009125825 ISSN: 0362-028X (43) Date of publication of application: • WALKER-CAPRIOGLIO H M ET AL: 13.08.2008 Bulletin 2008/33 "ANTIBODIES TO NYSTATIN DEMONSTRATE POLYENE STEROL SPECIFICITY AND ALLOW (73) Proprietor: Semorex Inc. IMMUNOLABELING OF STEROLS IN North Brunswick, NJ 08902 (US) SACCHAROMYCES CEREVISIAE" ANTIMICROBIAL AGENTS AND (72) Inventors: CHEMOTHERAPY, AMERICAN SOCIETY FOR • GREEN, Bernard, S. MICROBIOLOGY, WASHINGTON, DC, US, vol. 33, 76229 Rechovot (IL) no. 12, 1 December 1989 (1989-12-01), pages • TZOMIK, Inna 2092-2095, XP000999504 ISSN: 0066-4804 97299 Modiin (IL) • PALLAVI R M V ET AL: "Synthesis of the antigen • ARAD-YELLIN, Rina bovine serum albumin-ergosterol and its 76603 Rechovot (IL) immunocharacterization" FOOD AND AGRICULTURAL IMMUNOLOGY, XX, XX, vol.
    [Show full text]
  • Pharmaceutical Compositions Containing Oligomeric
    (19) TZZ ___T (11) EP 2 872 117 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) A61K 9/20 (2006.01) 27.09.2017 Bulletin 2017/39 A61K 31/19 (2006.01) A61K 31/765 (2006.01) A61P 15/02 (2006.01) C07C 69/68 (2006.01) (2006.01) (2006.01) (21) Application number: 13737191.0 C08L 67/04 A61K 9/08 A61K 47/38 (2006.01) A61K 9/70 (2006.01) A61K 31/225 (2006.01) (22) Date of filing: 05.07.2013 (86) International application number: PCT/EP2013/064265 (87) International publication number: WO 2014/012805 (23.01.2014 Gazette 2014/04) (54) PHARMACEUTICAL COMPOSITIONS CONTAINING OLIGOMERIC LACTIC ACID PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT OLIGOMERER MILCHSÄURE COMPOSITIONS PHARMACEUTIQUES CONTENANT DE L’ACIDE LACTIQUE OLIGOMÉRIQUE (84) Designated Contracting States: • SCHUBERT, Werner AL AT BE BG CH CY CZ DE DK EE ES FI FR GB S-436 44 Askim (SE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Chas. Hude A/S H.C. Andersens Boulevard 33 (30) Priority: 16.07.2012 DK 201270431 1780 Copenhagen V (DK) (43) Date of publication of application: (56) References cited: 20.05.2015 Bulletin 2015/21 WO-A1-2008/119518 WO-A2-03/016259 (73) Proprietor: Laccure Ab • SCHLIECKER G ET AL: "Characterization of a 252 20 Helsingborg (SE) homologous series of d,l-lactic acid oligomers; a mechanistic study on the degradation kinetics in (72) Inventors: vitro", BIOMATERIALS, ELSEVIER SCIENCE • STERNER, Olov PUBLISHERS BV., BARKING, GB, vol.
    [Show full text]
  • Functional Characterization of Leishmania Throughout in Vitro Biological Cycle: the Quest for a Quiescent Stage Among Amastigotes
    Faculty of Pharmacy, Biomedical and Veterinary Sciences Department of Biomedical Sciences Functional characterization of Leishmania throughout in vitro biological cycle: the quest for a quiescent stage among amastigotes Dissertation for the degree of Doctor in Biomedical Sciences at the University of Antwerp to be defended by Marlene Jara Portocarrero Promoters: Prof. Dr Jean-Claude Dujardin Prof. Dr. Jorge Arevalo Antwerp, 2019 Doctoral committee Chair Prof. Dr. Marleen Verhoye (University of Antwerp, Belgium) Member Prof. Dr. Paul Cos (University of Antwerp, Belgium) Prof. Dr. Kris Laukens (University of Antwerp, Belgium) Prof. Dr. Luc Kestens (University of Antwerp, Belgium) Prof. Dr. Michael Barrett (University of Glasgow) Prof. Dr. Michael Miles (London Centre for Neglected Tropical Disease Research) Promotors Prof. Dr. Jean-Claude Dujardin (Institute of Tropical Medicine, University of Antwerp, Belgium) Prof. Dr. Jorge Arevalo (Institute of tropical Medicine Alexander von Humboldt, UCPH, Lima, Peru) COLOFON Cover picture: Live cell imaging of peritoneal mouse macrophages infected with Leishmania mexicana. Dutch title Functionele karakterisering van Leishmania gedurende de gehele in vitro biologische cyclus: de zoektocht naar een slaaptoestand fase onder amastigoten. Acknowledgements I would like to thank my co-promotor Jorge Arevalo for fostering my interest in this peculiar pathogen called Leishmania throughout the years with interesting discussion and intriguing questions. However, doing a PhD was not on my mind therefore I would like to specially thank him and also to Manu Vanaerschot for encouraging me to pursue a PhD between the Institute of tropical Medicine Alexander von Humboldt (ITM AvH) and the Institute of Tropical Medicine of Antwerp (ITM) in the laboratory of Jean Claude.
    [Show full text]
  • TRANSPARENCY COMMITTEE OPINION 27 January 2010
    The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 ONYTEC 80 mg/g, medicated nail lacquer B/1 glass vial of 3.3 ml (CIP: 395 010-4) B/1 glass vial of 6.6 ml (CIP: 395 011-0) Applicant: BAILLEUL-BIORGA ciclopirox ATC code: D01AE14 Date of Marketing Authorisation: 01/07/2009 Reason for request : inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use. Medical, Economic and Public Health Assessment Division 1 1 CHARACTERISTICS OF THE MEDICINAL PRODUCT 1.1. Active ingredient ciclopirox 1.2. Originality ONYTEC is a water-soluble nail lacquer formulation based on ciclopirox. It rinses off in water. 1.3. Indication "Mild to moderate onychomycosis caused by dermatophytes and/or other ciclopirox-sensitive fungi, without lunula involvement. » 1.4. Dosage "Topical use on fingernails and toenails and immediately adjacent skin (perionychium, hyponychium). Unless otherwise specified, ONYTEC nail lacquer should be applied to the clean, dry affected nail(s) in a thin layer once a day. The medicated nail lacquer must be applied to the entire nail plate, 5 mm of surrounding skin and, if possible, to the free edge of the nail. ONYTEC nail lacquer takes about thirty seconds to dry. Treated nails must not be washed for at least six hours, and patients are therefore advised to apply the product in the evening before retiring. After this time the normal hygiene routine can be resumed. There is no need to use a solvent or abrasive (i.e. a nail file) to remove ONYTEC nail lacquer; washing the nails is sufficient.
    [Show full text]
  • Antifungals of the Azole Type
    RISK PROFILE Antifungals of the azole type This concerns azole type molecules used to eradicate or control fungi. They are used, or may potentially be used, for cosmetic purposes as defined in the European Commission database for cosmetic ingredients currently called CosIng. Date of reporting 24.11.201 4 This risk profile deviates in its format from other risk profiles in the series of pharmacological active substances as presented on the webpages of the Norwegian Food Safety Authority (NFSA). This is because the health risk arising because of use in cosmetics of these molecules mainly has to do with a potential worsening of the serious global problem of antimicrobial/antibiotic resistance/cross-resistance. The other risk profiles in this series concerns the toxicity of different cosmetics ingredients. The NSFA base this risk profile mainly on concerns expressed by the European Medicinal Agency (EMA) that on two occasions – in 2005 and 2011 - addressed the unfortunate use of azole type antifungals in cosmetics products. Also the NSFA observes that the same concern has been expressed by the Council of Europe in a publication as from 2008 concerning the use of Active ingredients in cosmetics. Over the years the Norwegian Medicinal Products Agency has strongly encouraged the NFSA forcefully to oppose any use of molecule in cosmetics that might potentially weaken the medicinal anti-fungus armamentarium against life threatening systemic fungal infections in people having a seriously compromised immune system. Over the years, also the European Commission has addressed this issue asking its scientific committee working in the field of cosmetic products - currently called the Scientific Committee on Consumer Safety (SCCS) - for advice.
    [Show full text]